[HTML][HTML] Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses
The neddylation inhibitor MLN4924/Pevonedistat is in clinical trials for multiple cancers.
Efficacy is generally attributed to cullin RING ligase (CRL) inhibition, but the contribution of …
Efficacy is generally attributed to cullin RING ligase (CRL) inhibition, but the contribution of …
[HTML][HTML] Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses
A Aubry, JD Pearson, J Charish, T Yu, JM Sivak… - Cell Reports, 2023 - Elsevier
The neddylation inhibitor MLN4924/Pevonedistat is in clinical trials for multiple cancers.
Efficacy is generally attributed to cullin RING ligase (CRL) inhibition, but the contribution of …
Efficacy is generally attributed to cullin RING ligase (CRL) inhibition, but the contribution of …
Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses
A Aubry, JD Pearson, J Charish, T Yu, JM Sivak… - Cell … - pubmed.ncbi.nlm.nih.gov
The neddylation inhibitor MLN4924/Pevonedistat is in clinical trials for multiple cancers.
Efficacy is generally attributed to cullin RING ligase (CRL) inhibition, but the contribution of …
Efficacy is generally attributed to cullin RING ligase (CRL) inhibition, but the contribution of …
Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses.
A Aubry, JD Pearson, J Charish, T Yu, JM Sivak… - Cell Reports, 2023 - europepmc.org
The neddylation inhibitor MLN4924/Pevonedistat is in clinical trials for multiple cancers.
Efficacy is generally attributed to cullin RING ligase (CRL) inhibition, but the contribution of …
Efficacy is generally attributed to cullin RING ligase (CRL) inhibition, but the contribution of …
Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses
A Aubry, JD Pearson, J Charish, T Yu, JM Sivak… - Cell Reports, 2024 - cell.com
(Cell Reports 42, 112925; August 29, 2023) In the originally published version of this paper,
the concentration of inhibitors for (C)–(F),(G)–(H), and (I)–(K) were not included. The …
the concentration of inhibitors for (C)–(F),(G)–(H), and (I)–(K) were not included. The …
Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses
A Aubry, JD Pearson, J Charish, T Yu, JM Sivak… - Cell Reports, 2023 - agris.fao.org
The neddylation inhibitor MLN4924/Pevonedistat is in clinical trials for multiple cancers.
Efficacy is generally attributed to cullin RING ligase (CRL) inhibition, but the contribution of …
Efficacy is generally attributed to cullin RING ligase (CRL) inhibition, but the contribution of …
Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses
A Aubry, JD Pearson, J Charish, T Yu, JM Sivak… - Cell …, 2023 - scholar.archive.org
(Cell Reports 42, 112925; August 29, 2023) In the originally published version of this paper,
the concentration of inhibitors for (C)–(F),(G)–(H), and (I)–(K) were not included. The …
the concentration of inhibitors for (C)–(F),(G)–(H), and (I)–(K) were not included. The …
[引用][C] Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses.
A Aubry, JD Pearson, J Charish, T Yu, JM Sivak… - Cell Reports, 2024 - europepmc.org
Deneddylation of ribosomal proteins promotes synergy between MLN4924 and
chemotherapy to elicit complete therapeutic responses. - Abstract - Europe PMC Sign in …
chemotherapy to elicit complete therapeutic responses. - Abstract - Europe PMC Sign in …
[引用][C] Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses
A Aubry, JD Pearson, J Charish, T Yu, JM Sivak… - Cell … - pubmed.ncbi.nlm.nih.gov